Cognition Therapeutics (CGTX)

• Market cap: $151M
• 1 day: -1.16%
• 5 days: -8.06%
• 1 month: 19.58%
• 3 months: 139.13%
• 6 months: 310.56%
• Year to date: 136.48%
• 1 year: 215.44%
• 5 years: -86.61%
• 10 years: -86.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25